A newly identified subtype of immune cell in the brain appears to help contain the damage associated with Alzheimer’s disease, according to a large-scale single-cell analysis published in Nature Genetics. The findings, led by researchers at the Icahn School of Medicine at Mount Sinai, could open a new therapeutic front that focuses on boosting the brain’s own defenses rather than targeting amyloid plaques alone.
Unprecedented Mapping of Brain Defenses
The study represents one of the most comprehensive surveys to date of myeloid immune cells in the human brain. The team analyzed more than 830,000 individual cells collected from the prefrontal cortex of 1,607 donors spanning a wide range of ages and stages of Alzheimer’s-related pathology.
By profiling these cells, the researchers identified six subclasses comprising 13 distinct subtypes of brain immune cells, including microglia — the central nervous system’s primary immune defenders — and perivascular macrophages, which help regulate immune responses around blood vessels in the brain.
“This mapping allowed us to track how these cellular populations change over the course of aging and as Alzheimer’s-associated alterations accumulate,” explained Donghoon Lee, Assistant Professor of Genetics and Genomic Sciences and of Psychiatry at Icahn Mount Sinai, who led the study.
A Protective Microglia Population Emerges
Among the subtypes identified, one particular population of microglia stood out: its numbers increased as Alzheimer’s pathology progressed, yet its behavior suggested a protective rather than harmful role. Instead of exacerbating neuronal damage, these cells showed enhanced capacity to engulf and clear toxic materials — a process known as phagocytosis.
“The data indicate that this microglia subtype doesn’t worsen brain damage,” Lee said. “On the contrary, it becomes more efficient at removing harmful substances from the brain environment.”
The Molecular Switch: TREM2, MITF, and GPNMB
The team traced the protective effect to a molecular pathway involving three key proteins: TREM2, MITF, and GPNMB. Experiments with both human brain tissue and mouse models showed that signaling through TREM2 — a protein already known to influence Alzheimer’s risk — is essential for maintaining microglia in this protective state.
The finding helps explain why genetic variants in immune-related genes such as TREM2 and APOE have been linked to elevated Alzheimer’s risk in previous studies. When the protective signaling pathway functions properly, microglia appear better equipped to limit damage; when it falters, the brain may become more vulnerable.
Key Takeaways from the Study
- Scale: More than 830,000 immune cells analyzed from 1,607 donors
- Classification: Six subclasses and 13 subtypes of myeloid cells mapped in the prefrontal cortex
- Discovery: A microglia population with a likely protective effect against Alzheimer’s damage
- Mechanism: The TREM2–MITF–GPNMB molecular axis is required to sustain the protective state
- Therapeutic implication: Multiple new molecular targets identified that could help slow disease progression
Shifting the Therapeutic Paradigm
Current Alzheimer’s treatments largely focus on reducing amyloid-beta plaques or tau tangles. The new work suggests an alternative strategy: fortifying the brain’s intrinsic immune defenses.
“By identifying the specific immune cells that appear to protect the brain and the molecular signals they depend on, we’ve uncovered new potential targets for therapies aimed at slowing the progression of Alzheimer’s disease,” Lee said.
The discovery could lead to drugs that either activate the protective microglia subtype or stabilize the TREM2–MITF–GPNMB pathway, effectively helping the brain fight back against degeneration. While translating these findings to the clinic will require further research, the study provides what Lee calls “the clearest view to date of how brain immune cells adapt during aging and Alzheimer’s disease” — and a promising roadmap for the next generation of treatments.
Source: Olhar Digital, Nature
